Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Metastatic colorectal carcinoma

To what extent does aspirin affect survival?

    • Congress Reports
    • Gastroenterology and Hepatology
    • Genetics
    • Oncology
    • RX
  • 4 minute read

More recently, studies have shown that aspirin improves overall survival in subgroups with colorectal cancer, specifically those with PIK3CA mutations. To test whether regular aspirin use is associated with survival in metastatic colorectal cancer, a study presented at ASCO GI in San Francisco collected data from two large academic institutions. In addition, experts discussed the impact of KRAS-NRAS status on second-line panitumumab therapy in patients with metastatic colorectal cancer.

(ag) The study, which examined the effects of regular aspirin use on metastatic colorectal cancer (CRC) or survival, was presented by Nishi Kothari, Tampa, at ASCO GI in San Francisco: “From two large academic institutions, namely the Moffitt Cancer Center in Tampa and the Royal Melbourne Hospital in Australia, we identified patients with PIK3CA-mutated CRC.”

In the two research centers, PIK3CA mutations were detected by exon sequencing (entirety of all exons). Prospective data, including age, sex, and disease location, as well as survival data, were available to the research team.

What can aspirin actually do?

In 2010, the best-known proponent of the “aspirin theory,” Peter M. Rothwell, compiled data from more than 14,000 CRC patients and concluded that aspirin not only reduced the incidence of this cancer by 24%, but also reduced its mortality by 35% [1]. In late 2012, Liao et al. concluded in their study [2] that regular aspirin use after CRC diagnosis was associated with longer survival, and only in patients with PIK3CA mutations. The values here reached statistical significance for both cancer-specific (p<0.001) and overall survival (p=0.01). Can these results be confirmed for PIK3CA-mutated metastatic CRC?
Kothari’s study identified a total of 187 CRC patients with a median age of 72 years and confirmed PIK3CA mutations, 26% of whom were taking aspirin regularly. One quarter of the participants suffered from metastatic disease at the time of diagnosis. Median follow-up was 48 months.

In univariate analyses of data from all subjects, aspirin use was not associated with significantly better overall survival (p=0.6), but there was a trend toward better cancer-specific survival (p=0.06).

No improvements at all in either overall or cancer-specific or recurrence-free survival were seen in patients with stage II or III disease (AICC classification).
However: in those at stage IV, regular aspirin use was indeed significantly associated with prolonged overall survival (p=0.04). A statistically significant association was also found for cancer-specific survival (p=0.02).

Significant improvement only in advanced disease stages

“What conclusion can be drawn from this recent study on aspirin in cancer therapy?” wondered Kothari in conclusion. “Well, our study is probably the largest investigation to date looking at regular aspirin use in PIK3CA-mutated metastatic CRC. It clearly shows that regular aspirin use may be associated with prolonged survival. However, not in all disease stages, but only in the more advanced ones.”
Of course, crucial limitations of the study should not go unmentioned: The results were not confirmed in the multivariate analysis. In addition, the analysis was retrospective with respect to aspirin use and information on therapy. Follow-up was also limited. “Our study should ultimately provide impetus to investigate the issue more deeply in prospective designs,” Kothari concluded.

RAS mutation status and panitumumab.

According to Marc Peeters, Edegem, large-scale studies have recently demonstrated two aspects of taking panitumumab (anti-EGFR) in the treatment of metastatic CRC: In combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan), it highly significantly improves progression-free survival compared with FOLFIRI alone (p=0.004) and shows a trend toward better overall survival (p=0.12) [3]. Second, another analysis [4] found that mutations in several RAS genes (KRAS/NRAS, exon 2, 3, 4) may predict nonresponse to panitumumab plus FOLFOX4 (oxaliplatin, fluorouracil, and leucovorin). Consequently, the inclusion of other mutations, complementary to the KRAS exon 2 status, seems crucial to predict therapeutic success.

“Our goal now was to investigate the extent to which treatment success in metastatic CRC is related to RAS status. Specifically, we were looking at progression-free and overall survival with panitumumab-FOLFIRI in the second-line setting,” Peeters said. “Patients with mutant RAS were found to benefit less from panitumumab addition (Table 1).

Not surprisingly, the same is true for those with mutated KRAS exon 2, which is, after all, already an established predictive biomarker. Of great relevance is the finding that participants with mutations in other RAS genes and a Kras exon 2 wild type also responded poorly to panitumumab. In addition, therapeutic success further improved when not only KRAS exon 2 but all RAS genes were wild type. Accordingly, our results are consistent with previous studies. The selection of patients for panitumumab therapy should be made by RAS testing,” Peeters concluded.

Source: “Cancers of the Colon and Rectum,” Oral Abstract Session at ASCO GI – Gastrointestinal Cancers Symposium, January 16-18, 2014, San Francisco.

Literature:

  1. Rothwell PM, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010 Nov 20; 376(9754): 1741-1750. doi: 10.1016/S0140-6736(10)61543-7. epub 2010 Oct 21.
  2. Liao X, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012 Oct 25; 367(17): 1596-1606. doi: 10.1056/NEJMoa1207756.
  3. Peeters M, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010 Nov 1; 28(31): 4706-4713.
  4. Douillard JY, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013 Sep 12; 369(11): 1023-1034. doi: 10.1056/NEJMoa1305275.

InFo Oncology & Hematology 2014; 2(2): 22-23.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • anti-EGFR
  • ASCO GI
  • Aspirin
  • cancer
  • CRC
  • Exon
  • FOLFIRI
  • KRAS-NRAS status
  • metastatic colorectal cancer
  • overall survival
  • Panitunumab
  • PIK3CA mutation
  • San Francisco
  • Wild type
Previous Article
  • Annual Swiss Psoriasis Day

Thematic aspects of psoriasis in a new light

  • Allergology and clinical immunology
  • Congress Reports
  • Dermatology and venereology
  • RX
View Post
Next Article
  • Follicular lymphoma

Rituximab in maintenance monotherapy.

  • Congress Reports
  • Hematology
  • Oncology
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.